Expression of somatostatin receptors in childhood neuroblastoma

C. L. Moertel, J. C. Reubi, B. S. Scheithauer, Daniel J Schaid, L. K. Kvols

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Somatostatin receptors are expressed on certain neural crest-derived tumors, including pancreatic islet cell and carcinoid tumors, medullary thyroid carcinomas, pheochromocytomas, and paragangliomas. The authors evaluated the expression of high affinity somatostatin receptors in childhood neuroblastoma using autoradiography techniques with the somatostatin analogue 125I-octreotide or 125I-[Leu8, D-Trp22, Tyr25]-SS-28 as the radioligand. Thirty tumors from 30 children with neuroblastoma were analyzed. Twenty-three of 30 tumors that were tested expressed somatostatin receptors. Correlation of somatostatin receptor expression with survival was statistically significant. The survival of those patients whose tumors expressed somatostatin receptors was of longer duration than that of patients whose tumors did not. This was an independent prognostic factor. Somatostatin receptors were expressed more frequently in tumor tissue from patients with lower stages of disease and in those with no evidence of N-myc amplification. Tumoral somatostatin receptors are expressed in a subgroup of patients with childhood neuroblastoma. Survival analysis in this group of patients indicates that somatostatin receptor expression is a favorable prognostic factor. This finding may have important implications for the therapy of children with this malignancy.

Original languageEnglish (US)
Pages (from-to)752-756
Number of pages5
JournalAmerican Journal of Clinical Pathology
Volume102
Issue number6
StatePublished - 1994
Externally publishedYes

Fingerprint

Somatostatin Receptors
Neuroblastoma
Neoplasms
Paraganglioma
Octreotide
Survival
Carcinoid Tumor
Pheochromocytoma
Survival Analysis
Somatostatin
Autoradiography

Keywords

  • Childhood malignancy
  • N- myc
  • Neuroblastoma
  • Neuroendocrine tumors
  • Octreotide
  • Somatostatin receptor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Moertel, C. L., Reubi, J. C., Scheithauer, B. S., Schaid, D. J., & Kvols, L. K. (1994). Expression of somatostatin receptors in childhood neuroblastoma. American Journal of Clinical Pathology, 102(6), 752-756.

Expression of somatostatin receptors in childhood neuroblastoma. / Moertel, C. L.; Reubi, J. C.; Scheithauer, B. S.; Schaid, Daniel J; Kvols, L. K.

In: American Journal of Clinical Pathology, Vol. 102, No. 6, 1994, p. 752-756.

Research output: Contribution to journalArticle

Moertel, CL, Reubi, JC, Scheithauer, BS, Schaid, DJ & Kvols, LK 1994, 'Expression of somatostatin receptors in childhood neuroblastoma', American Journal of Clinical Pathology, vol. 102, no. 6, pp. 752-756.
Moertel, C. L. ; Reubi, J. C. ; Scheithauer, B. S. ; Schaid, Daniel J ; Kvols, L. K. / Expression of somatostatin receptors in childhood neuroblastoma. In: American Journal of Clinical Pathology. 1994 ; Vol. 102, No. 6. pp. 752-756.
@article{a7df23f0d8b14722af49e104bcfae560,
title = "Expression of somatostatin receptors in childhood neuroblastoma",
abstract = "Somatostatin receptors are expressed on certain neural crest-derived tumors, including pancreatic islet cell and carcinoid tumors, medullary thyroid carcinomas, pheochromocytomas, and paragangliomas. The authors evaluated the expression of high affinity somatostatin receptors in childhood neuroblastoma using autoradiography techniques with the somatostatin analogue 125I-octreotide or 125I-[Leu8, D-Trp22, Tyr25]-SS-28 as the radioligand. Thirty tumors from 30 children with neuroblastoma were analyzed. Twenty-three of 30 tumors that were tested expressed somatostatin receptors. Correlation of somatostatin receptor expression with survival was statistically significant. The survival of those patients whose tumors expressed somatostatin receptors was of longer duration than that of patients whose tumors did not. This was an independent prognostic factor. Somatostatin receptors were expressed more frequently in tumor tissue from patients with lower stages of disease and in those with no evidence of N-myc amplification. Tumoral somatostatin receptors are expressed in a subgroup of patients with childhood neuroblastoma. Survival analysis in this group of patients indicates that somatostatin receptor expression is a favorable prognostic factor. This finding may have important implications for the therapy of children with this malignancy.",
keywords = "Childhood malignancy, N- myc, Neuroblastoma, Neuroendocrine tumors, Octreotide, Somatostatin receptor",
author = "Moertel, {C. L.} and Reubi, {J. C.} and Scheithauer, {B. S.} and Schaid, {Daniel J} and Kvols, {L. K.}",
year = "1994",
language = "English (US)",
volume = "102",
pages = "752--756",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "6",

}

TY - JOUR

T1 - Expression of somatostatin receptors in childhood neuroblastoma

AU - Moertel, C. L.

AU - Reubi, J. C.

AU - Scheithauer, B. S.

AU - Schaid, Daniel J

AU - Kvols, L. K.

PY - 1994

Y1 - 1994

N2 - Somatostatin receptors are expressed on certain neural crest-derived tumors, including pancreatic islet cell and carcinoid tumors, medullary thyroid carcinomas, pheochromocytomas, and paragangliomas. The authors evaluated the expression of high affinity somatostatin receptors in childhood neuroblastoma using autoradiography techniques with the somatostatin analogue 125I-octreotide or 125I-[Leu8, D-Trp22, Tyr25]-SS-28 as the radioligand. Thirty tumors from 30 children with neuroblastoma were analyzed. Twenty-three of 30 tumors that were tested expressed somatostatin receptors. Correlation of somatostatin receptor expression with survival was statistically significant. The survival of those patients whose tumors expressed somatostatin receptors was of longer duration than that of patients whose tumors did not. This was an independent prognostic factor. Somatostatin receptors were expressed more frequently in tumor tissue from patients with lower stages of disease and in those with no evidence of N-myc amplification. Tumoral somatostatin receptors are expressed in a subgroup of patients with childhood neuroblastoma. Survival analysis in this group of patients indicates that somatostatin receptor expression is a favorable prognostic factor. This finding may have important implications for the therapy of children with this malignancy.

AB - Somatostatin receptors are expressed on certain neural crest-derived tumors, including pancreatic islet cell and carcinoid tumors, medullary thyroid carcinomas, pheochromocytomas, and paragangliomas. The authors evaluated the expression of high affinity somatostatin receptors in childhood neuroblastoma using autoradiography techniques with the somatostatin analogue 125I-octreotide or 125I-[Leu8, D-Trp22, Tyr25]-SS-28 as the radioligand. Thirty tumors from 30 children with neuroblastoma were analyzed. Twenty-three of 30 tumors that were tested expressed somatostatin receptors. Correlation of somatostatin receptor expression with survival was statistically significant. The survival of those patients whose tumors expressed somatostatin receptors was of longer duration than that of patients whose tumors did not. This was an independent prognostic factor. Somatostatin receptors were expressed more frequently in tumor tissue from patients with lower stages of disease and in those with no evidence of N-myc amplification. Tumoral somatostatin receptors are expressed in a subgroup of patients with childhood neuroblastoma. Survival analysis in this group of patients indicates that somatostatin receptor expression is a favorable prognostic factor. This finding may have important implications for the therapy of children with this malignancy.

KW - Childhood malignancy

KW - N- myc

KW - Neuroblastoma

KW - Neuroendocrine tumors

KW - Octreotide

KW - Somatostatin receptor

UR - http://www.scopus.com/inward/record.url?scp=0028566555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028566555&partnerID=8YFLogxK

M3 - Article

C2 - 7801887

AN - SCOPUS:0028566555

VL - 102

SP - 752

EP - 756

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 6

ER -